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ABSTRACT 
Congenital adrenal hyperplasia (CAH) is 
generally regarded as a paediatric endocrine 
disease, but nowadays nearly all patients reach 
adulthood as a result of improved diagnosis and 
treatment. It is now increasingly recognised that 
treatment goals shift during life: one of the 
major treatment goals in childhood and puberty, 
i.e. normal growth and development, is no 
longer relevant after childhood, whereas other 
aspects, such as fertility and side effects of long-
term glucocorticoid treatment, become more 
important in adulthood. This paper focuses on 
fertility in male and female adult patients with 
CAH. In males with CAH the fertility rate is 
reduced compared with the normal population, 
the most frequent cause being testicular adrenal 
rest tumours. Development and growth of these 
tumours is assumed to be ACTH dependent and 
undertreatment may play an important role. If 
intensifying glucocorticoid treatment does not 
lead to tumour decrease, surgical intervention 
may be considered, but the effect on fertility is 
not yet known. In females with CAH the degree 
of fertility depends on the phenotype of the 
CAH. Most fertility problems are seen in the 
classic salt-wasting type. Age of menarche and 
regularity of the menstrual cycle depends on the 
degree of adrenal suppression. Not only adrenal 
androgens have to be normalised but also the 
levels of adrenal progestins (progesterone and 
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17-OH-progesterone) that interfere with normal 
ovulatory cycles. The regularity of menstrual 
cycles can be considered as an important mea-
sure of therapeutic control in adolescent females 
with CAH and therefore as a therapeutic goal 
from (peri)pubertal years on. Other factors that 
contribute to impaired fertility in females with 
CAH are ovarian hyperandrogenism (polycystic 
ovary syndrome), ovarian adrenal rest tumours, 
genital surgery and psychological factors. Sub-
fertility in CAH can have its origin already in the 
peripubertal years and is therefore of interest to 
the paediatric endocrinologist. 
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INTRODUCTION 
Congenital adrenal hyperplasia (CAH) is a 
disorder of adrenal steroid synthesis. In 95% of 
cases, it is caused by 21-hydroxylase deficiency, 
leading to Cortisol deficiency and (in most cases) 
aldosterone deficiency. The compensatory increase 
in adrenocorticotropin (ACTH) secretion by the 
pituitary gland leads to stimulation of the adrenals 
and, consequently, overproduction of androgens. 
The phenotype of 21-hydroxylase deficiency depends 
on the degree of enzyme deficiency. Complete 21-
hydroxylase deficiency leads to the classic salt-
wasting form with congenital virilization in females. 
Less severe 21 -hydroxylase deficiency results in the 
classic simple virilizing form without aldosterone 
deficiency. Patients with the mildest form, the late 
onset form of CAH, present with symptoms caused 
by androgen excess only: pseudoprecocious puberty, 
hirsutism, menstrual irregularities and infertility1. 
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Treatment of 21-hydroxylase deficiency consists 
of glucocorticoid supplementation and in case of 
aldosterone deficiency also mineralocorticoid sup-
plementation. 
In the past, CAH was generally regarded as a 
paediatric endocrine disease, but nowadays nearly 
all patients reach adulthood as a result of improved 
diagnosis and treatment. Thus, the spectrum of 
CAH as a lifelong chronic disease becomes 
gradually clear, and it is increasingly recognised 
that treatment goals shift during life: the major 
treatment goals in childhood and puberty, i.e. 
normal growth and development, are no longer 
relevant after childhood, whereas other aspects, 
such as fertility and the side effects of long-term 
glucocorticoid treatment, become more important 
in adulthood. In this paper we focus on fertility in 
adult male and female patients with CAH. 
FERTILITY IN MALE PATIENTS WITH 
CONGENITAL ADRENAL HYPERPLASIA 
There is evidence that fertility is impaired in 
males with CAH. Jääskeläinen et al. found a 
significantly lower child rate (0.07) in 16 male 
patients with CAH compared with an age matched 
Finnish male control group (0.34)2. Other studies 
report child rate only as additional information in 
selected patient populations3"5. An alternative 
method to investigate fertility in men is semen 
analysis. Wuesthof et al. reported normal semen 
analysis in only 34% of 53 males with CAH4. 
Cabrera et al. reported abnormal semen analysis in 
46% of 16 investigated patients5. In our own series, 
only four of 11 men with CAH had a normal sperm 
count6. However, not all patients are willing to 
collect semen for analysis. Measurement of serum 
follicle stimulating hormone (FSH) and inhibin Β 
levels is also used to assess fertility in men with 
CAH. Several studies report abnormal FSH levels, 
indicating Sertoli cell damage2'3,5'6. However, it 
should be noted that in CAH patients with primary 
testicular damage, serum gonadotropin levels might 
be suppressed due to high levels of adrenal 
androgens. Most of these patients also have serum 
testosterone levels within the normal range, which 
is the result of conversion of adrenal androgens to 
testosterone. In this situation a more reliable 
predictor of testicular damage is the serum inhibin 
Β level, which reflects Sertoli cell function. 
The most important cause of infertility in men 
with CAH is the presence of testicular tumours 
resulting in primary gonadal failure. Another 
important factor contributing to infertility is the 
suppression of the hypothalamic-pituitary-gonadal 
axis due to high circulating levels of androgens 
resulting in secondary gonadal failure. 
Testicular adrenal rest tumours 
Testicular tumours in male patients with CAH 
are thought to arise from aberrant adrenal cells in 
the testes that are stimulated by ACTH7. Therefore 
they are called testicular adrenal rest tumours. 
Testicular adrenal rest tumours have also been 
described in other conditions with high plasma 
ACTH levels, such as Nelson's syndrome or 
Addison's disease8'9. However, testicular tumours 
are also found in well-controlled patients with 
CAH, with normal or suppressed ACTH5'6. The 
reported prevalence of testicular adrenal rest 
tumours in males varies between 0% and 94%, 
depending on the selection of the patients and the 
method of detection2'3,5'6'10'". In our own series, 
one or more testicular tumours were found in 16 of 
17 patients (age 16-40 years). Ultrasound seems to 
be the best method for detection and follow up, 
especially in the case of small non-palpable 
tumours12. Testicular tumours have also been 
reported in patients under the age of 16 years10'13,14. 
We now routinely follow our male children with 
CAH (n = 25;age 6-19 years) with ultrasound and 
detected seven boys with small, mostly non-
palpable tumours, the youngest patient being 7 years 
old (unpublished data). The testicular tumours, 
which are always located in the mediastinum testis, 
can lead to obstruction of the vascular supply and 
compression and atrophy of the seminiferous 
tubules. In addition to these mechanical effects, 
steroids produced by the tumours could be toxic to 
testicular tissue (paracrine effect) therefore contri-
buting to testicular failure15. These two factors 
result in primary gonadal failure with elevated 
gonadotropin levels and low inhibin Β levels. 
Therefore treatment or prevention of the develop-
ment of testicular tumours is an important goal. 
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Poor hormonal control with inadequate suppres-
sion of ACTH may be a main factor in the aetiology 
of testicular tumours16"18. By increasing the gluco-
corticoid dose, ACTH secretion is suppressed and 
the adrenal rest tissue is no longer stimulated, 
which may lead to testicular tumour shrinkage. The 
need for tumour shrinkage and the side effects of 
increasing glucocorticoid therapy must be carefully 
balanced, especially in asymptomatic patients1 . 
The effect of medical treatment is described mostly 
in case reports or in small patient groups and the 
results vary dependent on patient selection, type of 
CAH and treatment choice14'20"24. Rutgers et al. 
reported tumour shrinkage in 75% of 16 patients 
after increasing the glucocorticoid dose21. Walker 
et al. reviewed 75 cases of testicular tumours in 
CAH and stated that the majority of the masses 
regressed with an increase in glucocorticoid dose22. 
Rich et al. reported testicular tumours in three 
young patients (5, 15 and 17 years old). Intensifying 
the glucocorticoid therapy resulted in normalising 
the elevated steroid levels in all patients. However, 
in no case were the tumours resolved, and there was 
partial regression in only one patient14. In our own 
study population we also found unpredictable 
results2 : tumour decrease was found in six of the 
15 male patients with CAH after intensifying 
glucocorticoid therapy, but tumour decrease was 
also seen in one patient with undertreatment. 
Tumour increase was also seen in patients with 
adequate treatment. Use of dexamethasone instead 
of hydrocortisone in the night resulted in better 
adrenal suppression in only one of our patients. 
Therefore general guidelines for glucocorticoid 
strategies cannot been given, and the decision for 
dose and timing of glucocorticoid treatment has to 
be made individually in all patients, with special 
attention to side effects. 
If tumour size does not decrease with increasing 
glucocorticoid therapy or if there is persistent azoo-
spermia despite tumour shrinkage, surgical inter-
vention may be considered22,25. In the past orchiec-
tomy was performed. However the malignant 
potential of these tumours is negligible26. Walker et 
al. performed testis sparing surgery in three patients 
with CAH22. Postoperatively there was good 
vascular flow and no recurrence of the tumour. 
However investigations to assess fertility were not 
performed. Tiryaki et al. reported two male CAH 
patients with steroid unresponsive testicular 
tumours who were also treated by testis sparing 
tumour enucleation25. Again no data about fertility 
before and after operation were reported. Because 
fertility prognosis in CAH males with testicular 
tumours remains uncertain, cryopreservation of 
semen could be proposed to young adult male 
patients. In case of unwanted infertility, assisted 
reproduction could be considered. When there is 
obstructive azoospermia, testicular aspiration and 
intracytoplasmatic sperm injection may offer a 
solution1 . At least in some cases deterioration of 
fertility by testicular tumour growth can be 
prevented by early increase of glucocorticoid 
therapy. Furthermore, early testis sparing surgery as 
soon as testicular tumours are detected has the 
potential to prevent damage to the testicular tissue. 
Therefore it may be that detection of the tumours 
by ultrasonography at an early stage (prepubertal) is 
useful. However, further investigations are neces-
sary to support this hypothesis. 
Hypogonadotropic hypogonadism 
In poorly controlled patients with CAH the 
elevated ACTH levels induce high levels of andro-
stenedione, which is partly aromatised to oestron. 
These high levels of androgens and oestron will 
suppress the hypothalamic-pituitary-gonadal axis, 
leading to hypogonadotropic hypogonadism and 
small testes17,1 27. It may be that steroids produced 
by testicular adrenal rest tumours contribute to the 
suppression of the hypothalamic-pituitary-gonadal 
axis. However this effect cannot be separated from 
the effects resulting from adrenal androgen excess. 
Hypogonadotropic hypogonadism may also 
occur in males with previously undiagnosed late 
onset 21-hydroxylase deficiency. In this condition 
adrenal rest tumours are not a common finding. 
Most reports show reversible hypogonadism and 
improved fertility after initiating or increasing 
glucocorticoid therapy28,29. 
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FERTILITY IN WOMEN WITH 
CONGENITAL ADRENAL HYPERPLASIA 
In women with CAH due to 21-hydroxylase 
deficiency, fertility seems to be reduced, based on 
reports of decreased pregnancy rates, decreased 
live-birth rates and menstrual disorders30'31. 
Most reports about pregnancies in female 
patients with classic 21-hydroxylase deficiency are 
case studies. There are only a few reports providing 
pregnancy rates or live-birth rates in large popu-
lations of patients with CAH32"36: the live-birth rate 
in patients with classic salt-wasting CAH is 0-10% 
(n = 64), in simple virilizing patients 33-50% (n = 
83) and in non-classic patients 63-90% (n = 18). In 
the general population or in age-matched controls, 
• IS 
pregnancy rates or live-birth rates are 65-91% " . 
Thus, compared with a non-CAH female popula-
tion, pregnancy and live-birth rates are severely 
reduced in patients with salt-wasting CAH, mildly 
reduced in patients with simple virilizing CAH, and 
normal in patients with non-classic CAH. Preg-
nancy outcomes in women with classic CAH have 
been reviewed by Lo and Grumbach37. They found 
105 reported pregnancies in 73 women with CAH 
(20 salt-wasting patients, 53 simple virilizing 
patients), resulting in 74 live-born children. Of 
these 105 pregnancies, 11 (10%) led to spontaneous 
abortion and 11 (10%) were electively terminated. 
Data on fertility in patients with non-classic 21-
hydroxylase deficiency are predominantly derived 
from studies in patients in whom the diagnosis of 
CAH was made after they had presented with 
subfertility and/or other symptoms of hyperandro-
genism. As a result, these fertility data represent 
only the symptomatic subset of the non-classic 
CAH population, and this introduces substantial 
bias. It has become clear that the prevalence of non-
classic CAH is relatively high, but when the disease 
is mild, patients may never come to clinical 
presentation. In two reports on fertility in non-
classic patients presenting with subfertility, the 
corrected pregnancy rate was 93% and 100%38'39, 
spontaneously or after glucocorticoid treatment 
(with or without clomiphene citrate). 
Instead of pregnancy rates and live-birth rates as 
direct markers of fertility, regularity of menstrual 
cycles can be used as an indirect marker of fertility, 
particularly in adolescent girls. In most reports, a 
normal mean age of menarche was observed in girls 
with CAH40"42, but these data are misleading 
because by definition only the patients who did 
experience menarche were included. In women 
with CAH, delayed menarche can be associated 
with poor therapeutic control. Menstrual irregu-
larity in women with CAH has also been associated 
with poor therapeutic control41 and in non-classical 
CAH, menstrual irregularity is typically one of the 
presenting signs. 
Several factors have been suggested to contri-
bute to impaired fertility in females with CAH: 
adrenal overproduction of androgens and progestins 
(17-hydroxyprogesterone and progesterone), ovarian 
hyperandrogenism (polycystic ovary syndrome), 
ovarian adrenal rest tumours, genital surgery, and 
psychological factors such as delayed psychosexual 
development, reduced sexual activity and low 
maternal feelings. 
Adrenal overproduction of androgens and 
progestins 
Androgen overproduction by the adrenal gland 
can directly and indirectly affect ovarian activity. 
Directly, androgen excess inhibits ovarian folliculo-
genesis. The hypothesis that androgen excess has a 
negative (direct and/or indirect) effect on ovulation 
is supported by the finding that suppression of 
adrenal androgen secretion by increasing the gluco-
corticoid dose can restore ovulation in patients with 
CAH. However, in some patients adequate suppres-
sion of androgen levels was not sufficient to correct 
menstrual abnormalities. In these patients, increas-
ed levels of progestins (progesterone and 17-
hydroxyprogesterone) as a result of adrenal over-
production interfered with normal menstrual 
cycles34'41·43·44. 
Elevated progestin levels may cause persistent 
inhibition of follicular growth, inhibition of endo-
metrial proliferation and failure of endometrial 
breakdown, resulting in menstrual disorders. In 
addition, even if regular ovulation and menstruation 
is achieved, elevated progesterone levels from 
adrenal origin can still prevent conception in 
women with CAH, by causing involution of the 
endometrium and impermeability of the cervical 
45 mucus . 
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Thus, adequate suppression of adrenal andro-
gens and progestins is needed for menarche and 
regular menstrual cycles. In reverse, the regularity 
of menstrual cycles can be considered as a measure 
of therapeutic control in females with CAH and 
should be aimed at from pubertal years on. 
Hypogonadotropic hypogonadism 
Similar to male patients with CAH, oversecre-
tion of androgens, which are mostly aromatized to 
oestron, can result in hypogonadotropism, contri-
buting to anovulation or dysovulation. Adequate 
suppression of androgens can help to restore 
gonadotrophin cyclicity and therefore regular men-
strual cycles. However, in contrast to the experi-
ence in male patients with CAH, these findings are 
rare in female patients46'47. 
Polycystic ovarian syndrome (PCOS) 
PCOS is characterized by ovulatory dysfunction 
and hyperandrogenism with irregular menstrual 
cycles, hirsutism and acne, leading to subfertility. 
In the classic form polycystic ovaries are detected. 
The pathogenesis of PCOS is still uncertain but 
there is evidence that the androgens result from 
ovarian overproduction48. Female patients with 
CAH with poor hormonal control as well as un-
treated women with the non-classic form of CAH 
can have a similar clinical presentation, including 
sonographic evidence of ovarian cysts resulting 
from adrenal hyperandrogenism. In both conditions 
significantly elevated levels of androgens, 17-
hydroxyprogestrone and insulin insensitivity have 
been described49"52. So the distinction between 
these two conditions can be difficult. Differenti-
ation can be made upon post-ACTH rise in 17-
hydroxyprogestrone and molecular analysis ' . 
Because PCOS is associated with reduced fertility54 
it is suggested that the presence of PCOS in 
patients with CAH can be an additional factor in 
the mechanism of subfertility in women with 
CAH1'55. Stikkelbroeck et al. investigated the pre-
valence of PCOS in 13 female patients with CAH. 
Polycystic ovaries were found in two patients 
(15.4%) reflecting a prevalence corresponding to 
the general population56. Therefore it is unlikely 
that PCOS is a frequent cause of infertility in 
women with CAH. 
Ovarian adrenal rest tumours 
In contrast to the high prevalence of testicular 
tumours in male patients with CAH, ovarian 
adrenal rest tumours have been described only in 
case reports57"59. In our own study of 13 women 
with CAH, no ovarian adrenal rest tumours could 
be detected either by ultrasonography or by mag-
netic resonance imaging (MRI), which suggests that 
ovarian adrenal tumours are rare and do not fre-
quently contribute to female subfertility56. Therefore 
routine ovarian imaging in these patients is not 
indicated. 
Genital surgery 
Besides the endocrine factors described above, 
the effects of genital surgery in early life also play 
an important role in impaired fertility in women 
with CAH. Surgical reconstruction of ambiguous 
genitalia in 46,XX neonates consists of reduction of 
clitoral size, creation of labia minora and exterioris-
ation of the vagina, thereby creating a functional 
vagina to allow menstruation and sexual activity60'61. 
The most important factors related to surgery that 
can interfere with sexual disturbance are loss of 
clitoral sensitivity, intravaginal stenosis and distur-
bed vaginal arousal62. In the past in female 
neonates with clitoromegaly, clitoridectomy was 
performed with loss of sensitivity due to damage to 
the neurovascular supply. Currently the preferred 
technique is clitoroplasty with excision of the 
erectile tissue preserving the neurovascular supply 
to the glans63. However, recent data show that there 
is still abnormal clitoral sensation even after 
optimising the surgical technique62. The incidence 
of vaginal stenosis after surgery varies dependent 
on the type of operation64'65. In the past stenosis 
was reported in up to 77%81. Krege et al. reported 
vaginal stenosis in 36% of patients, with a require-
ment for additional treatment (manual dilatation, 
secondary vaginoplasty)66. Therefore modern surgi-
cal techniques performed by experienced surgeons 
can improve the functional results of the surgery. 
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Psychosexual factors 
Several studies show gender atypical behaviour 
in female patients with CAH67'75. It is suggested 
that biological and social factors contribute to the 
development of gender identity disorders in these 
patients. Pre- and postnatal exposure to androgens 
can cause gender atypical behaviour resulting in 
more boyish behaviour, such as preference for male 
typical toys and admiration for male characters. 
Furthermore, significantly less satisfaction with the 
/ - o 
female sex of assignment is reported . However, 
social factors can also influence the development of 
gender identity, such as inability of parents to cn 
accept the sex assignment . These gender identity 
disorders can contribute to subfertility in female 
patients with CAH69. There is controversy about the 
rate of bisexuality or homosexuality. Other psycho-
social factors can be anxiety about sexual activity 
and inability to achieve orgasm. 
CONCLUSION 
Congenital adrenal hyperplasia and its treatment 
have a considerable impact on fertility in both 
males and females. It is important to recognize that 
the majority of causes impairing fertility are already 
present in childhood, and therefore should be a 
treatment goal already in (peri)pubertal years. CAH 
should therefore be regarded as a lifelong disease: 
the implications of CAH and its treatment reach 
beyond childhood. 
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